Vincerx Pharma Inc（VINC）の株式分析VINCVincerx Pharma Inc

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and oncology knowledge to advance new therapies to address unmet medical needs for the treatment of cancer. The Company’s pipeline consists of enitociclib, which is in Phase I, and a modular bioconjugation platform, which includes a small molecule drug-conjugate (SMDC), VIP236, in Phase I, and preclinical next-generation antibody drug-conjugates, VIP943 and VIP924. Enitociclib, is a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. The Company's antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors. VIP236 is a SMDC with a focus on treating patients with cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).